NCT02442440 (ACIdoSIS) is a Phase 1/Phase 2 clinical trial of anisodamine in Septic Shock, sponsored by Jinhua Central Hospital.

Who is sponsoring NCT02442440?

NCT02442440 is sponsored by Jinhua Central Hospital.

What drugs are being tested in NCT02442440?

Interventions in NCT02442440: anisodamine.

What condition does NCT02442440 study?

NCT02442440 studies Septic Shock.

Is NCT02442440 still recruiting?

NCT02442440 is currently completed. Last updated 23 September 2021.

Last reviewed 2021-09-23 · How we verify

NCT02442440: ACIdoSIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Anisodamine for the Treatment of Critically Ill Patients With Septic Shock: a Randomized Controlled Trial

Completed Phase 1/Phase 2 Last updated 23 September 2021

What this trial tests

Phase 1/Phase 2 trial testing anisodamine in Septic Shock in 355 participants. Completed in 1 October 2020.

Timeline

1 April 2015

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Jinhua Central Hospital
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	355
Start date	1 April 2015
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	15 locations across China

Drugs / interventions tested

anisodamine — full drug profile →

Conditions studied

Septic Shock — all drugs for Septic Shock →

Sponsor

Jinhua Central Hospital

Who can join

15 and older, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

hospital mortality
Time frame: from ICU admission to hospital discharge (participants will be followed for the duration of hospital stay, an expected average of 28 days)
the outcome will be assessed by using proportion of patients died, and relative risk will be reported.

Sponsor's own description

Anisodamine has been widely used in China for its pharmacological effect on improving microcirculation during shock. It has been reported that anisodamine is effective in reducing mortality rate in children with meningitis. however, its effectiveness in patients with septic shock has not been systematically investigated. The aim of the study is to investigate the effectiveness of anisodamine in the treatment of patients with septic shock.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial.
Yu Y, Zhu C, Hong Y, Chen L, et al · · 2021 · cited 20× · PMID 34579741 · DOI 10.1186/s13054-021-03774-4
A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma.
Zheng Y, Li Y, Liu X, Zhang R, et al · · 2017 · cited 11× · PMID 28203424 · DOI 10.21037/jtd.2017.01.44
Effectiveness of anisodamine for the treatment of critically ill patients with septic shock (ACIdoSIS study): study protocol for randomized controlled trial.
Zhang Z, Zhou J, Shang Y, Wang X, et al · · 2015 · cited 4× · PMID 26605292 · DOI 10.3978/j.issn.2305-5839.2015.10.03

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other Jinhua Central Hospital trials

Trials by the same sponsor.

NCT06769685 — TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II · enrolling by invitation
NCT06204094 — Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02442440 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jinhua Central Hospital
Last refreshed: 23 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02442440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing